PDCD1 and neoplasm: Preclinical assays showed that dual blockade of PD-1 and CTLA-4 combined with GM-CSF gene-transfected tumor cell vaccine (GVAX) in murine models of CRC resulted in tumor rejection in 100% of mice [93].